NovaBiotics its participating in this year’s ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance taking place between 6^th and 8^th September in Boston, Massachusetts.

The conference brings together leading health professionals who are at the forefront of the battle against the urgent global health problem of antimicrobial resistance (AMR).

The NovaBiotics team will present recent data on their novel drug candidates developed from the company's intelligent drug design platforms in response to AMR in bacteria and fungi. Details of the posters can be found below:

Wednesday 6th September /Thursday 7th September - 1545-1645/1530-1630

Cysteamine is a Component of our Innate Immune Defence, Capable of Potentiating Antibiotic Activity Against Priority MDR Pathogens

Wednesday 6th September /Thursday 7th September - 1545-1645/1530-1630

NP108, a broad-specturm antimicrobial polymer in development for the treatment of wound infections

Wednesday 6th September /Thursday 7th September - 1545-1645/1530-1630

NP339 (Novamycin): a novel antifungal peptide solution to the fungal resistance threat

Wednesday 6th September /Thursday 7th September - 1545-1645/1530-1630

NP432, a novel antimicrobial peptide rapidly active against multi-drug resistant bacteria